To overcome this inconvenience, restoration of FoxO3a expression and/or activity [26,55], which translates in the regulation of FoxO3a multiple transcriptional targets, including integrin α5, could represent a promising and reliable approach to be exploited as an adjuvant to antiestrogen therapy in stratified BC patients that are refractory to the treatment. The gene discussed is FOXO3; the disease is breast cancer.